Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crenigacestat - Eli Lilly and Company

Next Previous
Drug Profile

Crenigacestat - Eli Lilly and Company

Alternative Names: JSMD-194; LY-3039478

Latest Information Update: 30 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Fred Hutchinson Cancer Research Center; National Cancer Institute (USA)
  • Class Amides; Antineoplastics; Benzazepines; Fluorinated hydrocarbons; Pyridines; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Precursor T-cell lymphoblastic leukaemia-lymphoma
  • No development reported Cancer; Liver cancer; Lymphoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 01 Aug 2025 Eli Lilly and Company terminates a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Denmark, France and Spain, due to business considerations (PO) (NCT02784795)
  • 08 Jan 2024 Fred Hutchinson Cancer Research Center in collaboration with Juno Therapeutics terminates a phase-I trial in Multiple myeloma in USA (PO) due to SRC low accrual policy (NCT03502577)
  • 30 May 2023 Eli Lilly and Company completes a phase-I trial in Solid tumours in Japan (NCT02836600)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top